Breakthrough Patent for Next-Generation Filler Technology

Koru Pharma has successfully registered a groundbreaking patent for our next-generation filler technology, which innovatively eliminates the need for chemical cross-linking agents. This achievement marks a significant milestone in our continuous efforts to develop safer and more effective aesthetic solutions.

Our newly patented hyaluronic acid-chitosan cross-linking filler technology utilises only natural materials, ensuring the highest safety standards without compromising the superior physical properties and quality of our fillers. Traditional fillers often rely on chemical cross-linking agents, raising concerns about potential toxicity. Our innovative approach addresses these concerns, paving the way for safer and more versatile filler formulations.

This revolutionary technology not only enhances product safety but also opens up new possibilities for overcoming the limitations of existing fillers. By expanding the capacity and potential applications of fillers, we are excited to explore new horizons in the aesthetic industry.

A spokesperson for Koru Pharma highlighted, “This technology is a game-changer. By eliminating chemical cross-linking agents, we secure the safety of our products while enabling various advancements in filler applications. We are committed to leveraging these research results to continue developing and commercialising next-generation hyaluronic acid fillers.”

Founded in 2016, Koru Pharma has rapidly become a leader in K-beauty exports, with our primary products, including filler injections and skin boosters, reaching approximately 120 countries worldwide, including 41 in Europe. As we look to the future, our goal is to become the No. 1 Health Care & Beauty company, showcasing the competitiveness of K-beauty and revolutionising the market with our innovative aesthetic treatments.

Join us in celebrating this remarkable achievement as we continue our journey to redefine beauty and safety in the medical aesthetic industry.

Source: https://biz.heraldcorp.com/article/3429360